Atossa Genetics Announces FDA Acceptance of Its Investigational New Drug Application to Begin a Phase II Clinical Trial of Fulvestrant for the Treatment of DCIS
September 21, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 21, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast...
Atossa Genetics Receives Approval to Begin Clinical Study in Israel
September 08, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 8, 2015) - Atossa Genetics (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast health...
Atossa Genetics Inc. to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
September 04, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 4, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast...
Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer
September 02, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 2, 2015) - Atossa Genetics, Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast...
Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update; Achieves Total Revenue for Q2 2015 of $2.7 Million
August 06, 2015 16:01 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 6, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced second quarter 2015 financial results and provided an update on recent company...
Atossa Genetics to Announce Second Quarter 2015 Financial Results and Provide a Company Update on Thursday, August 6, 2015
August 05, 2015 11:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 5, 2015) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will issue financial results and corporate developments for the Second Quarter ended June 30,...
Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement for Atossa's Lead Drug Candidate Afimoxifene Gel
August 05, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 5, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that it has signed manufacturing and quality agreements with AAIPharma...
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTAG Platform
July 22, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jul 22, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that its subsidiary, The National Reference Laboratory for Breast Health Inc. (the NRLBH), now...
Atossa Genetics Announces Acquisition of Ductal Lavage Specimen Bank From the Dr. Susan Love Research Foundation
July 01, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jul 1, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that it has acquired a specimen bank from Dr. Susan Love Research...
Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast Cancer Detection Using Absorbent Paper
June 11, 2015 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 11, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that the U.S. Patent and Trademark Office has issued a new patent, Serial...